Merck EBIT 2010-2024 | MRK
Merck annual and quarterly EBIT history from 2010 to 2024. EBIT can be defined as earnings before interest and taxes.
- Merck EBIT for the quarter ending September 30, 2024 was $3.984B, a 32.15% decline year-over-year.
- Merck EBIT for the twelve months ending September 30, 2024 was $14.160B, a 73.68% increase year-over-year.
- Merck 2023 annual EBIT was $2.954B, a 83.84% decline from 2022.
- Merck 2022 annual EBIT was $18.282B, a 38.51% increase from 2021.
- Merck 2021 annual EBIT was $13.199B, a 137.91% increase from 2020.
Merck Annual EBIT
(Millions of US $) |
| 2023 |
$2,954 |
| 2022 |
$18,282 |
| 2021 |
$13,199 |
| 2020 |
$5,548 |
| 2019 |
$7,926 |
| 2018 |
$8,931 |
| 2017 |
$6,797 |
| 2016 |
$5,499 |
| 2015 |
$7,547 |
| 2014 |
$6,683 |
| 2013 |
$7,665 |
| 2012 |
$9,877 |
| 2011 |
$8,976 |
| 2010 |
$3,355 |
| 2009 |
$4,021 |
Merck Quarterly EBIT
(Millions of US $) |
| 2024-09-30 |
$3,984 |
| 2024-06-30 |
$6,128 |
| 2024-03-31 |
$5,760 |
| 2023-12-31 |
$-1,712 |
| 2023-09-30 |
$5,872 |
| 2023-06-30 |
$-5,012 |
| 2023-03-31 |
$3,806 |
| 2022-12-31 |
$3,487 |
| 2022-09-30 |
$4,106 |
| 2022-06-30 |
$5,067 |
| 2022-03-31 |
$5,622 |
| 2021-12-31 |
$3,751 |
| 2021-09-30 |
$4,923 |
| 2021-06-30 |
$1,696 |
| 2021-03-31 |
$2,829 |
| 2020-12-31 |
$-3,376 |
| 2020-09-30 |
$2,507 |
| 2020-06-30 |
$2,436 |
| 2020-03-31 |
$3,981 |
| 2019-12-31 |
$-1,554 |
| 2019-09-30 |
$2,614 |
| 2019-06-30 |
$3,458 |
| 2019-03-31 |
$3,408 |
| 2018-12-31 |
$2,852 |
| 2018-09-30 |
$2,664 |
| 2018-06-30 |
$2,266 |
| 2018-03-31 |
$1,149 |
| 2017-12-31 |
$2,036 |
| 2017-09-30 |
$146 |
| 2017-06-30 |
$2,532 |
| 2017-03-31 |
$2,083 |
| 2016-12-31 |
$-991 |
| 2016-09-30 |
$3,070 |
| 2016-06-30 |
$1,657 |
| 2016-03-31 |
$1,763 |
| 2015-12-31 |
$1,952 |
| 2015-09-30 |
$2,340 |
| 2015-06-30 |
$1,737 |
| 2015-03-31 |
$1,518 |
| 2014-12-31 |
$1,526 |
| 2014-09-30 |
$1,700 |
| 2014-06-30 |
$1,404 |
| 2014-03-31 |
$2,053 |
| 2013-12-31 |
$1,897 |
| 2013-09-30 |
$2,465 |
| 2013-06-30 |
$1,485 |
| 2013-03-31 |
$1,818 |
| 2012-12-31 |
$1,964 |
| 2012-09-30 |
$2,370 |
| 2012-06-30 |
$2,785 |
| 2012-03-31 |
$2,758 |
| 2011-12-31 |
$1,995 |
| 2011-09-30 |
$2,376 |
| 2011-06-30 |
$2,406 |
| 2011-03-31 |
$2,199 |
| 2010-12-31 |
$-441 |
| 2010-09-30 |
$1,420 |
| 2010-06-30 |
$1,443 |
| 2010-03-31 |
$933 |
| 2009-12-31 |
$-234 |
| 2009-09-30 |
$1,640 |
| 2009-06-30 |
$1,421 |
| 2009-03-31 |
$1,194 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$244.211B |
$60.115B |
|
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
|
